Skip to main content
OpenTrials
Completed

NCT Number: NCT00157326

Tadalafil in Subjects With Mild to Moderate Hypertension

Purpose: The primary objective of this study is to evaluate the efficacy and safety of tadalafil when administered once daily at doses of 5 and 20 mg to adult subjects for 8 weeks with mild to moderate hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Bothell, Washington, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have a documented medical history of hypertension.
  • Have cuff seated diastolic blood pressure values greater than or equal to 95 and less than or equal to 104 mm at study entry
  • Have a negative serum pregnancy test at the time of enrollment and agree to use two medically reliable methods of contraception until study completion, if female is of child-bearing potential, between menarche and 1 year post menopause and not surgically sterilized.
  • Are able to comply with study procedures and visits

Exclusion criteria

  • Have resistant hypertension or systolic hypertension.
  • Are obese, defined as having body mass index (BMI) greater than or equal to 35.
  • Are females who are pregnant or breast feeding.
  • Have a history of severe renal insufficiency or significant thyroid, renal or hepatic disease.
  • Have a glycosylated hemoglobin A1c (HbA1c) greater than or equal to 10% during the screening period.
  • Have significant anemia.
  • Have a significant or unstable cardiac history such as history of heart attack, unstable angina, or stroke within 6 months of study entry, history of angina that was treated with long- or short-acting nitrates within 90 days of study entry, history of coronary artery bypass graft surgery or cardiac angioplasty within 90 days of study entry, history of abnormal heart rhythms such as sick sinus syndrome or 2nd- or 3rd-degree AV block, chronic atrial fibrillation or recurrent atrial tachyarrhythmia, a history of recurrent ventricular tachycardia, or symptomatic bradycardia, a history of sudden cardiac arrest.
  • Have symptomatic heart failure requiring treatment, or significant disease of the heart valves.
  • Have been treated for severe asthma, bronchospasm, or COPD within 3 months of study entry.
  • Have severe peripheral vascular disease.
  • Have a documented diagnosis of sleep apnea.

Treatment and study plan

Tadalafil

Drug

Other names: LY450190, Cialis, IC351

Primary outcomes

  1. The primary efficacy measurement of this study is the mean change after 8 weeks of treatment from baseline in cuff seated trough diastolic blood pressure, cuff seated systolic blood pressures and automated blood pressure monitoring

Secondary outcomes

  1. Safety will be assessed by evaluating all reported adverse events and changes in clinical laboratory values, ECGs, and vital signs

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Collaborators

  • ICOS Corporation

Registry information

Official study title

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Tadalafil (5mg and 20mg) Administered Once Daily to Subjects With Mild to Moderate Hypertension

Important dates

Study start
2005
Study completion
2006
First posted
Sep 12, 2005
Registry last updated
Oct 25, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.